Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises
27 juni, 15:10
Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises
Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).
During the period June 5 – June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises.
After this, the Company's new registered share capital is NOK 41,452,224.60 divided into 69,087,041 shares, each with a nominal value of NOK 0.60.
Advisors
In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
For further information, please contact:
Tore Grøttum, Interim Chief Financial Officer
E-mail: tg@genetic-analysis.com
Ämnen i artikeln
Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises
27 juni, 15:10
Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises
Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).
During the period June 5 – June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises.
After this, the Company's new registered share capital is NOK 41,452,224.60 divided into 69,087,041 shares, each with a nominal value of NOK 0.60.
Advisors
In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
For further information, please contact:
Tore Grøttum, Interim Chief Financial Officer
E-mail: tg@genetic-analysis.com
Ämnen i artikeln
-1-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
Mest läst
Marknadsöversikt
OMX Stockholm 30
1 DAG %
2,26%
Senast
2 506,17
1 mån
Loading market data...
Privatekonomi med Placeras expert
Affärsvärlden
-992x558.jpg&w=3840&q=75)